DOI QR코드

DOI QR Code

The ERCC1 C118T Polymorphism Predicts Clinical Outcomes of Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Meta-analysis Based on 22 Studies

  • Qian, Ying-Ying (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Liu, Xin-You (Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University) ;
  • Wu, Qian (Department of Neurology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Song, Xian (Department of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Pathogen Biology, Nanjing Medical University) ;
  • Chen, Xiao-Feng (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Liu, Yi-Qian (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Pei, Dong (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Shen, Li-Zong (Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University) ;
  • Shu, Yong-Qian (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University)
  • Published : 2014.10.23

Abstract

Background: Although the predictive value of the excision repair cross-complementing group 1 (ERCC1) C118T polymorphism in clinical outcomes of patients with colorectal cancer (CRC) receiving oxaliplatin-based chemotherapy has been evaluated in numerous published studies, the conclusions are conflicting. Therefore, we performed the present meta-analysis to determine the precise role of the ERCC1 C118T polymorphism in this clinical situation and help optimize individual chemotherapy. Materials and Methods: A multiple search strategy was used to identify eligible studies. Pooled odds ratios (ORs) and their 95% confidence intervals (CIs) were used to estimate objective response and oxaliplatin-induced toxicity, with hazard ratios (HRs) with 95%CIs for progression-free survival (PFS) and overall survival (OS). Results: A total of 22 studies including 2,846 CRC patients were eligible in the analysis. Overall, no significant correlation was found between the ERCC1 C118T polymorphism and objective response to oxaliplatin-based chemotherapy, in all patients or in the Asian and Caucasian subgroups. However, the pooled analysis showed that the PFS and OS were significantly shorter in patients who carried T/T or T/C genotypes of ERCC1 C118T as compared to the C/C genotype. On stratified analysis by ethnicity, the ERCC1 118T allele was associated with a favorable prognosis in Caucasians (PFS, HR=0.58, 95%CI: 0.24-1.44; OS, HR=0.38, 95%CI: 0.22-0.64) but an unfavorable prognosis in Asians (PFS, HR=2.49, 95%CI: 1.87-3.33; OS, HR=2.63, 95%CI: 1.87-3.69) based on a dominant model. In addition, we failed to find a statistically significant impact of ERCC1 C118T polymorphism on oxaliplatin-induced toxicity. Conclusions: The ERCC1 C118T polymorphism may have prognostic value in patients with CRC undergoing oxaliplatin-based chemotherapy.

Keywords

ERCC1;oxaliplatin;prognosis;chemotherapy;meta-analysis

References

  1. Reed E (2005). ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res, 11, 6100-2. https://doi.org/10.1158/1078-0432.CCR-05-1083
  2. Yue AM, Xie ZB, Zhao HF, et al (2013). Associations of ABCB1 and XPC genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis in a Chinese population. Asian Pac J Cancer Prev, 14, 3085-91. https://doi.org/10.7314/APJCP.2013.14.5.3085
  3. Zhang ZY, Tian X, Wu R, et al (2012). Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 13, 2583-6. https://doi.org/10.7314/APJCP.2012.13.6.2583
  4. Raymond E, Chaney SG, Taamma A, et al (1998). Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol, 9, 1053-71. https://doi.org/10.1023/A:1008213732429
  5. Ruzzo A, Graziano F, Loupakis F, et al (2007). Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol, 25, 1247-54. https://doi.org/10.1200/JCO.2006.08.1844
  6. Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41. https://doi.org/10.3322/caac.21149
  7. Spindler KL, Andersen RF, Jensen LH, et al (2010). EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. Ann Oncol, 21, 535-9. https://doi.org/10.1093/annonc/mdp336
  8. Stoehlmacher J, Park DJ, Zhang W, et al (2004). A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer, 91, 344-54.
  9. Viguier J, Boige V, Miquel C, et al (2005). ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res, 11, 6212-7. https://doi.org/10.1158/1078-0432.CCR-04-2216
  10. Sun XH, Hou WG, Zhao HX, et al (2013). Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors. Asian Pac J Cancer Prev, 14, 2049-52. https://doi.org/10.7314/APJCP.2013.14.3.2049
  11. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
  12. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16. https://doi.org/10.1186/1745-6215-8-16
  13. Vilmar A, Sorensen JB (2009). Excision repair crosscomplementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer, 64, 131-9. https://doi.org/10.1016/j.lungcan.2008.08.006
  14. Woelfelschneider A, Popanda O, Lilla C, et al (2008). A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis, 29, 1758-64. https://doi.org/10.1093/carcin/bgn067
  15. Yang J, Wang ZG, Cai HQ, et al (2013). Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy. Asian Pac J Cancer Prev, 14, 4595-8. https://doi.org/10.7314/APJCP.2013.14.8.4595
  16. Yin M, Yan J, Martinez-Balibrea E, et al (2011). ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res, 17, 1632-40. https://doi.org/10.1158/1078-0432.CCR-10-2169
  17. Boige V, Mendiboure J, Pignon JP, et al (2010). Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol, 28, 2556-64. https://doi.org/10.1200/JCO.2009.25.2106
  18. Ahmad S (2010). Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers, 7, 543-66. https://doi.org/10.1002/cbdv.200800340
  19. Alberts SR, Horvath WL, Sternfeld WC, et al (2005). Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol, 23, 9243-9. https://doi.org/10.1200/JCO.2005.07.740
  20. Altman DG, Bland JM (2003). Interaction revisited: the difference between two estimates. BMJ, 326, 219. https://doi.org/10.1136/bmj.326.7382.219
  21. Braun MS, Richman SD, Quirke P, et al (2008). Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol, 26, 2690-8. https://doi.org/10.1200/JCO.2007.15.5580
  22. Cassidy J, Clarke S, Diaz-Rubio E, et al (2008). Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol, 26, 2006-12. https://doi.org/10.1200/JCO.2007.14.9898
  23. Chai H, Pan J, Zhang X, et al (2012). ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese. Int J Clin Exp Med, 5, 186-94.
  24. Chang PM, Tzeng CH, Chen PM, et al (2009). ERCC1 codon 118 C-->T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci, 100, 278-83. https://doi.org/10.1111/j.1349-7006.2008.01031.x
  25. Chen YC, Tzeng CH, Chen PM, et al (2010). Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci, 101, 530-5. https://doi.org/10.1111/j.1349-7006.2009.01418.x
  26. Faivre S, Chan D, Salinas R, et al (2003). DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol, 66, 225-37. https://doi.org/10.1016/S0006-2952(03)00260-0
  27. Cheng J, Ha M, Wang Y, et al (2012). A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. J Cancer Res Clin Oncol, 138, 231-8. https://doi.org/10.1007/s00432-011-1090-1
  28. Chua W, Goldstein D, Lee CK, et al (2009). Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer, 101, 998-1004. https://doi.org/10.1038/sj.bjc.6605239
  29. Cortejoso L, Garcia MI, Garcia-Alfonso P, et al (2013). Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol, 71, 1463-72. https://doi.org/10.1007/s00280-013-2145-6
  30. Fakih MG, Bullarddunn K, Yang GY, et al (2008). Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys, 72, 650-7. https://doi.org/10.1016/j.ijrobp.2008.01.020
  31. Farina Sarasqueta A, van Lijnschoten G, Lemmens VE, et al (2011). Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers? Mol Diagn Ther, 15, 277-83. https://doi.org/10.1007/BF03256419
  32. Huang MY, Huang ML, Chen MJ, et al (2011). Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics, 21, 18-25. https://doi.org/10.1097/FPC.0b013e3283415124
  33. Inada M, Sato M, Morita S, et al (2010). Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther, 48, 729-34. https://doi.org/10.5414/CPP48729
  34. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  35. Lamas MJ, Duran G, Balboa E, et al (2011). Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics, 12, 433-42. https://doi.org/10.2217/pgs.10.196
  36. Kang S, Sun HY, Zhou RM, et al (2013). DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy. Asian Pac J Cancer Prev, 14, 941-6. https://doi.org/10.7314/APJCP.2013.14.2.941
  37. Kumamoto K, Ishibashi K, Okada N, et al (2013). Polymorphisms of , and -3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncol Lett, 6, 648-54.
  38. Kwon HC, Roh MS, Oh SY, et al (2007). Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol, 18, 504-9.
  39. Lee KH, Chang HJ, Han SW, et al (2013). Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer Chemother Pharmacol, 71, 843-51. https://doi.org/10.1007/s00280-013-2075-3
  40. Li H-Y, Ge X, Huang G-M, et al (2012). GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population. Asian Pac J Cancer Prev, 13, 3465-9. https://doi.org/10.7314/APJCP.2012.13.7.3465
  41. Liang J, Jiang T, Yao RY, et al (2010). The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol, 66, 493-500. https://doi.org/10.1007/s00280-009-1186-3
  42. Liang J, Lv H, Yao R, et al (2008). ERCC1 Asn118Asn polymorphism as predictor for cancer response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer. Chinese-German J Clin Oncol, 7, 455-9. https://doi.org/10.1007/s10330-008-0086-z
  43. Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res, 14, 1291-5. https://doi.org/10.1158/1078-0432.CCR-07-2238
  44. Noda E, Maeda K, Inoue T, et al (2012). Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer. Hepatogastroenterology, 59, 130-3.
  45. Martinez-Balibrea E, Abad A, Aranda E, et al (2008). Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer, 44, 1229-37. https://doi.org/10.1016/j.ejca.2008.03.025
  46. Moreno V, Gemignani F, Landi S, et al (2006). Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res, 12, 2101-8. https://doi.org/10.1158/1078-0432.CCR-05-1363
  47. Nishina T, Takano Y, Denda T, et al (2013). A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients. Jpn J Clin Oncol, 43, 1080-6. https://doi.org/10.1093/jjco/hyt127
  48. Oguri T, Mitsuma A, Inada-Inoue M, et al (2013). Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. Int J Clin Pharmacol Ther, 51, 475-81. https://doi.org/10.5414/CP201851
  49. Pare L, Marcuello E, Altes A, et al (2008). Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer, 99, 1050-5. https://doi.org/10.1038/sj.bjc.6604671

Cited by

  1. gene alters the efficacy of narrowband ultraviolet B therapy in patients with active vitiligo in a Chinese population vol.173, pp.2, 2015, https://doi.org/10.1111/bjd.13892
  2. Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients vol.17, pp.7, 2016, https://doi.org/10.2217/pgs-2015-0017
  3. Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis vol.17, pp.15, 2016, https://doi.org/10.2217/pgs-2016-0102